Management

Senior Leadership Team

Tim Benner

Chief Commercial Officer

Tim joins Inari with more than 16 years of senior leadership experience with high-growth and transformational medical technology companies. Most recently, Tim spearheaded the global launch and commercial execution of Saluda Medical’s disruptive closed-loop neuromodulation platform. Before joining Saluda, Tim was the Global GM and SVP of Terumo’s Blood and Cell Technologies business. Prior to joining Terumo, Tim was responsible for commercial leadership of the U.S. Structural Heart business at Abbott and oversaw the execution of hyper-growth therapies such as MitraClip, Amulet, and Portico. Tim joined Abbott after approximately 10 years at Edwards Lifesciences where he oversaw several functions across Global Marketing, Commercial Operations, Global Strategy, and Business Development. Tim also worked in a commercial capacity with Endologix, as well as Honda Motor. At Honda, he worked in R&D and spearheaded Advanced Product Development initiatives.

Neil Bhalodkar

Vice President of Investor Relations

Neil joined Inari in 2024 with over two decades of experience in investor relations, corporate finance, and equity research. Most recently, he led the investor relations function at Axonics, Inc., a high-growth medical technology company based in Irvine, for four years until its acquisition by Boston Scientific. He previously held a similar role at Sientra, Inc., a medical aesthetics company based in Santa Barbara. Prior to moving to corporate, Neil spent eight years at Bank of America and Lehman Brothers advising healthcare clients on equity, debt, and M&A transactions. Neil also has six years of experience conducting fundamental research and analysis on public healthcare companies as a sell-side equity research analyst. Neil earned a B.S. in finance and accounting from the Stern School of Business at New York University.

Shon Chakrabarti, MD MPH

Chief Medical Officer, LimFlow

Dr. Shon Chakrabarti first joined Inari Medical in 2021 with an extensive background in patient care, clinical research, and innovation including multiple roles in industry. He completed his residency training at the University of Michigan in 2009 and General and Interventional Cardiology fellowships at the Beth Israel Deaconess Medical Center – Harvard Medical School in 2014, with a master’s degree in Clinical Effectiveness from the Harvard School of Public Health. Following Fellowship, Shon provided front-line Interventional Cardiology care for patients in Southern Virginia. Dr. Chakrabarti’s first industry role was with Abiomed, where he served as Director of Clinical Research and Medical Affairs and provided medical leadership across the Abiomed Clinical Trial Platform. During his time at Inari Medical, Dr. Chakrabarti first served as Vice President, Medical Affairs, providing cross-functional expertise across departments, before taking a role as VP and General Manager, Chronic Venous Therapies and building a national market development team to identify and improve outcomes for patients suffering from chronic venous disease. As CMO of LimFlow, Dr. Chakrabarti will continue to lead an important function and business unit for Inari, focused on improving outcomes for Chronic Limb Threatening Ischemia (CLTI) patients with a novel, breakthrough therapy.

Tara Dunn

Senior Vice President & General Manager, LimFlow

Tara joined Inari in 2016 with executive responsibilities spanning marketing, clinical, regulatory, and quality. Recently, Tara was appointed the General Manager of LimFlow, Inari’s first acquisition and business unit. Prior to Inari, Tara helped establish Volcano Corporation's (acquired by Philips) peripheral business unit where she led the Venous Business Segment. Before Volcano, Tara was in Corporate Development at Medtronic working on a range of transactions including the divestiture of its Physio-Control business unit and the acquisition of China-based Kanghui Holdings. Before Medtronic, Tara's background spanned various roles at Health Advances, a healthcare strategy consulting firm and at InfraReDx, a start-up (acquired by Nipro). Tara earned an AB in Biology from Harvard University, an MS in Regulatory Affairs and Health Policy from the Massachusetts College of Pharmacy, and an MBA from Harvard Business School. Tara was a member of Harvard's National Championship-winning ice hockey and Ivy League championship-winning softball teams. She also competed in the National Women’s Hockey League (NWHL) for two seasons.

Drew Hykes

Chief Executive Officer

Drew Hykes has served as our Chief Executive Officer and President and as a member of our Board since January 2023. Mr. Hykes is a proven medical device operating executive with broad functional, geographic and sector experience. From September 2020 until December 2022, Mr. Hykes served as our Chief Operating Officer leading the day-to-day business operations. From September 2017 to September 2020, he served as our Chief Commercial Officer. From 2012 to 2016 Mr. Hykes served as the VP of Commercial Operations at Sequent Medical where he led the commercialization strategy for the WEB Aneurysm Embolization system from early prototype to broad adoption in the European market. Prior to Sequent, Mr. Hykes spent 11 years at Medtronic. His roles at Medtronic included the VP of Marketing for the AF Solutions business, VP of Clinical and Regulatory for the AF Solutions business and Director of Investor Relations. Mr. Hykes also spent three years on an expatriate assignment in Europe leading the launch of Medtronic’s first drug eluting coronary stent. Prior to Medtronic, he spent four years at ABN AMRO bank in Chicago focused on healthcare transactions. Mr. Hykes holds a B.B.A. in Finance from the University of Wisconsin and an MBA from Harvard Business School.

Eric Khairy

Senior Vice President of Marketing

Eric holds over 15 years of medical device experience in marketing, sales, strategy, and product development. Following the acquisition of Volcano by Philips in 2016, Eric progressed from leading global peripheral venous marketing to driving strategy of the peripheral vascular segment at Philips Image-Guided Therapy Devices. Joining Corindus Vascular Robotics in the company’s pre-commercial phase in 2012, Eric launched the first FDA cleared robotic-assisted system for percutaneous coronary interventions. Prior to Corindus, Eric led Intuitive Surgical’s launch and distribution of the da Vinci Surgical System in the Canadian market at Minogue Medical. Eric earned a B.Eng. in computer engineering from McGill University, an M.A.Sc. in biomedical engineering from the University of Montreal, and an MBA from the Sloan School of Management at MIT.

Mazi Kiani

Senior Vice President of Quality and Regulatory

Mazi joined Inari in 2024 with over two decades of experience in Quality, Regulatory, and Clinical Affairs. Most recently, he held executive leadership roles at iRhythm Technologies and Siemens Healthineers. Mazi earned a B.S. in Chemical Engineering from the University of Washington. After earning his degree, Mazi's professional journey began at Fred Hutchinson Cancer Research Center before making a transition into the medical device field at Edwards Lifesciences. Throughout his career, he has held key leadership positions at Boston Scientific, Veranex, Siemens Healthineers, and iRhythm Technologies. At Siemens, Mazi was the SVP of Quality, Regulatory, and Clinical Affairs leading all aspects of Quality, Compliance, Clinical Affairs, and Regulatory Affairs for the Ultrasound business unit. Most recently, at iRhythm, he was the Global Head of the Quality and Regulatory function for the company.

Paul Koehn

Senior Vice President of Operations

Paul brings to Inari over 25 years of experience in high volume, high quality growth operations across multiple industries. With experience both in domestic and global strategic planning, Paul’s work in product development and production has resulted in 4 revolutionary device platforms and 150 total products. Paul has a excellent track record in overall business performance exceeding 80% gross margin on all products, 92% gross margin on devices, and established scalable production and distribution capacity to greater than 4 times demand. In addition, Paul also brings a understanding of construction of manufacturing facilities and corporate offices. Paul was most recently the Senior Vice President of Quality and Operations at Cardiovascular Systems Inc. where he was crucial in the growth of the company from $0 revenue in 2007 to over $200M in 2017.

Andrew Niekamp, MD

Vice President of Medical Affairs

Prior to joining Inari, Dr. Niekamp was a Vascular Interventional Radiologist with Radiology Associates of South Florida and joined the group in July of 2020. He also practiced at Baptist Hospital of Miami, South Miami Hospital and Doctors Hospital. Dr. Niekamp received his undergraduate degree and medical degree from The Ohio State University and completed his post-graduate training at the University of Texas at Houston/M.D. Anderson Cancer Center. He completed his fellowship in Vascular Interventional Radiology at the Miami Cardiac and Vascular Institute. Following fellowship, he joined the faculty at Miami Cardiac and Vascular Institute and was a practicing attending until March 2024. Dr. Niekamp has been an investigator in multiple clinical research trials and is the author of numerous papers and abstracts. During his time in practice, Dr. Niekamp had a particular focus on treating patients suffering from venous thromboembolism.

Hussain Rangwala

Chief Technology Officer

Hussain Rangwala brings over 16 years of leadership in medical device innovation, with a proven track record of driving impactful technologies that improve patient outcomes. He has a PhD in Mechanical and Aerospace Engineering from State University of New York with research in the development and evaluation of medical devices. His background spans significant roles at Medtronic and MicroVention Terumo, where he most recently served as CTO and Head of Global Operation, leading a global team of over 2,000 in the development and manufacture of neurovascular devices. With 50+ patents and deep expertise in developing technologies for multiple disease states, Hussain has a strong legacy of introducing transformative products to the market, shaping the future of medical care.

Kevin Strange

Chief Financial Officer

Kevin brings nearly 20 years of medical device experience in corporate development (M&A and venture capital), strategy, finance, equity research and sales. Kevin joined Inari in 2020 as VP, Strategy and Business Development. Since 2023 he has served as the SVP, Finance, Accounting, Strategy and Business Development leading Inari’s day to day financial and accounting operations. Prior to joining Inari, he has over 15 years of experience in various financial and business development leadership roles within the medical device space. Kevin was appointed to Chief Financial Officer in 2024. Prior to Inari, Kevin was the Director of Business Development for the Peripheral Interventions division of Boston Scientific, where he helped transform the business from $1B of annual sales to over $1.7B. Kevin’s deal experience spans multiple acquisitions, divestitures and venture investments. Prior to Boston Scientific, Kevin worked as an equity research analyst at Wells Fargo Securities and Bank of America Merrill Lynch covering the MedTech sector. Kevin started his career in medical devices in the Cardiac Rhythm Management division of Medtronic. Kevin holds a BS in Biology from Davidson College and an MBA from New York University’s Stern School of Business.

Vic Tapson, MD

Vice President of Medical Affairs

Dr. Tapson became interested in acute DVT/PE in the early 1990s, with his earliest research in catheter-directed PE therapy and MR imaging of acute and chronic DVT. He continued with research in all areas of acute VTE, and at the same time, co-funded the Duke Lung Transplant and Duke Pulmonary Hypertension Programs. He enrolled patients in ICOPER in 1990s, and served as PI for a number of national and international PE trials and registries including IMPROVE, NABOR, ENDORSE, OPTALYSE PE, the TAFI inhibitor trial and the BiO2 Angel catheter trial. He served as co-PI for DVT-FREE, the FLARE trial, and many others. After joining Inari, he stepped down from the executive committee for HI PEITHO and Thrombolex trials. He has seen either inpatients or outpatients with acute or chronic PE as well as pulmonary hypertension patients almost daily for decades. He ran Covid trials at Cedars during the pandemic. He was elected to the Royal College of Physicians in 2010. Dr. Tapson has lectured on PE in more than 50 countries.

Shannon Trevino

General Counsel

Shannon has served as Inari's General Counsel and Corporate Secretary since November 2024. Shannon joined Inari in 2023 with over 15 years of legal experience. Prior to Inari, she served as Director of the Transactional Lawyering Institute at Loyola Law School while also maintaining a part-time corporate law practice with Sugg Law Group. Shannon previously held a Counsel role at Latham & Watkins LLP, where she advised clients on a variety of corporate transactions, including mergers and acquisitions, capital raising, IPOs and licensing deals, as well as corporate governance matters. Her clients spanned several industries, including life sciences, healthcare, med tech, real estate and finance. Shannon earned an AB from Princeton University in the Princeton School of Public and International Affairs and her JD from Loyola Law School.

Tom Tu, MD

Chief Medical Officer

Dr. Thomas Tu joins Inari Medical after practicing Interventional Cardiology for 16 years. He is a graduate of Harvard Medical School and completed residency at Massachusetts General Hospital. He was trained in Interventional Cardiology, Peripheral Vascular Intervention, and Structural Heart Disease at Beth Israel Deaconess Medical Center. Most recently, he was the Cath Lab director and leader of the Pulmonary Embolism, complex PCI, and TAVR programs at Baptist Health Louisville. Dr. Tu helped develop the early phase technology that allowed Inari Medical to optimize patient outcomes. He also served as the presenter for the FLARE IDE trial of the Inari FlowTriever Retrieval/Aspiration System. This study led to FDA 510 (k) clearance for treatment of pulmonary embolism, the first thrombectomy device cleared for that indication.